This purpose of this project is to build a prototype instrument that will, running unattended, detect, identify, and quantify BW agents. In order to accomplish this, we have chosen to start with the world's leading, proven, assays for pathogens: surface-molecular recognition assays, such as antibody-based assays, implemented on a high-performance, identification (ID)-capable flow cytometer, and the polymerase chain reaction (PCR) for nucleic-acid based assays. With these assays, we must integrate the capability to:
Introduction
Although we face numerous credible threats, to date the US has no acceptable autonomous system for the detection, identification, and quantification of airborne pathogens. Such a system is needed to provide protection to the occupants of large buildings or other enclosed-airspace facilities, such as subways or other gathering sites.
A detection/identification system could be used in at least three ways: detect-to-warn; detectto-treat; detect-to-restore. In the detect-to-restore mode, the user may accept a manual-or semiautomated-processing instrument that would be used to help delineate the contaminated area and to verify the efficacy of any decontamination procedures; subcomponents of the autonomous system could find use in such operations. In the detect-to-warn and detect-to-treat modes, however, a rapid, autonomous operation is needed. Obviously, planning on the part of the authorities is needed to be able to respond to an alarm -relatively inexpensive HEPA-filtered masks could be donned in the detect-to-warn mode, and quarantine/limited travel of exposed persons would be the appropriate in the detect-to-treat mode, followed by the administering of selected antibiotics, etc.
To be acceptable, the autonomous system will have to satisfy the following criteria:
1 . It must be able to run, unattended, for 24-hour periods (and much longer periods than this are preferable). 2. It must be capable of the automatic, positive detection, identification, and quantification of the pathogens. 3. It must be capable of positive detection and identification of the items listed under #2 at aerosol concentrations of 1 agent-containing particlefliter of air (ACPLA) or greater in the presence of all normal environmental airborne backgrounds, including diesel exhaust, smoke, pollen, nonpathogenic bacteria and spores, etc. 4. It should detect and identify in less than 20 minutes for 5 ACPLA concentrations or higher, and less than 35 minutes for 1 ACPLA concentration. Quantification of the threat is highly desirable.
5. It must have a false-alarm rate that is less than 1 per year.
We are currently working to build such an autonomous system, which we call the "BioSentry", using flow cytometry for surface-recognition assays, PCR for nucleic-acid-based assays, and sample collection/preparation instrumentation, along with commercial bio-aerosol collectors. We have selected the flow-cytometric and PCR assays because they have proven themselves, worldwide, as the most powerful assays, other than cell culture. We are not including cell culture, due to its long duration for growth of the samples, its labor-intensive identification, and its inability to detect non-culturable organisms.
Performance considerations for B. anthracis (B.a.)
Starting with 1 ACPLA of B.a., where one particle for B.a. could be assumed to consist of In order to avoid false positives, however, a threshold for calling a positive might be set higher than 2.5 X 1O spores/mi. Assuming that the flow assay required 5 minutes after the aerosol collection, which is reasonable, then there would be sufficient time to obtain the results from the PCR assay, using a tiered detection system, for verification of the detection/ID/quantification. The most rapid real-time PCR assays that we have require roughly 15 minutes to detect i07 spores/mi, and require roughly 25 minutes for i03 spores/mi. The inverse of the time (actually the number of thermal cycles) that is required before the automated caffing of a positive detection/ID by the instrument' s software is an estimate of the starting concentration of the organism being detected via PCR + Taqman®, and could be used to confirm the results of the flow-based assay. It is our belief that the level of certainty that is required to call an alarm for a public gathering site requires the use of two or more assays with independent, complementary signatures. False alarms are not acceptable, as we have already indicated in criterion #5, above. These considerations demonstrate that a Bio-Sentry should be an achievable system.
Necessary Subcomponents for the Autonomous System
Aerosol sample collector: There are numerous bio-aerosol sample collectors that are commercially available. Of these, only the XM2®, from SCP, Inc., has a pre-collection fractionator (PCF) to reject outsized particles. When viewed in a systems perspective, a PCF is very important, since rejecting outsized particles prevents the clogging of fluidic lines that are necessary for sample preparation and assays. Unfortunately, the design of the PCF on the XM-2 is one that requires a large, heavy, power-hungry air pump. Under support from the DoD's Fluidics system: In order to have an autonomous system, we must have the customized, automated fluidics to transport and prepare the collected samples for the assays. We are developing this using small discrete valves, tubing, and chambers (see Figure 2) , and we are perfecting the various operational steps that include reagent storage and dispensing, sample preconcentration, incubating with reagents, self-disinfecting, etc., all under computer control that also starts and monitors the assays so that positive detection is automatically called and communicated. There are several companies that have the capability to reduce such fluidic systems to small plastic-based fluidic "circuits", once we have perfected the detailed, automated operations that are required.
Detector/Identifiers with quantitative assays: The world community has already thoroughly investigated the techniques that can be used, under manual operation, to detect and identify pathogens, and these are: culture, nucleic-acid-based assays, and antibody-based assays (Ab-based). The leading nucleic-acid-based assays use the polymerase chain reaction (PCR). Culturing an organism is slow and does not always pick up pathogens that might require a specific host tissue or environment; this is especially true of viral agents. Speaking in a tautology, the culture technique simply does not pick up organisms that are non-viable or nonculturable. Ab-based assays are the fastest to perform, but are confounded by difficulties associated with non-specific binding of the reagents. This problem is exacerbated when using environmentally collected aerosols due to Ab binding to dirt, pollen, molds, spores, etc. which can also generate false positives.
Over the last ten years, PCR has made major inroads into the detection and identification of pathogens, and, while it is typically a slower process than Ab-based assays, it offers highly complementary information that, when used in conjunction with Ab-based assays, provides the most complete signature. In particular, it provides the strongest approach to identifying engineered organisms and allowing attribution of the agent. False alarms destroy the credibility of detectors, and it is relatively easy to "beat" a single assay. Therefore, we plan on incorporating both Ab-based assays and PCR as the assays to be in the Bio-Sentry. As additional technologies such as mass spectroscopy become more mature and reliable for biodetection, we can incorporate those additional signatures into the system.
Status of the Bio-Sentry
Bio-aerosol collectors Under the DOE CBNP Program, we have obtained and have performed preliminary evaluations of the performance of the leading aerosol collectors. Figure 1 shows our measurements for three leading aerosol collectors and the all-glass impinger (AGI), a highefficiency, low-throughput unit. As we mentioned, above, with support from the CMO we designed and built a new type of PCF, that has shown improved performance, with greatly reduced power requirements. 
Flu idics System
With support from the DOE Chem-Bio Non-Proliferation (CBNP) program, we have designed. built, and tested a small breadboarded fluidics system to perform sample preparation for the flow-cytometric Ab-based assay. This fluidics system. connected to miniFlo, is shown in Figure 3 . The focus of our current effort is to build a robust system for mixing the sample solution with the Ab solution for incubation, prior to running the assay. Figure 2 . Photograph of R. Miles, testing the fluidics system connected to the miniFlo.
Flow instrumentation
In 1993 we invented a new method to detect scattered light in flow cytometers, the flowstream-waveguide technique. and built several instruments using this principIe2.When the opportunity arose to build a "luggable" version for use in the DoD's Joint Field Trials III (JFT III). we did so over a 4-month period. We used this flow cytometer. dubbed "miniFlo", to run antibody assays for the four BW simulants that were used as unknowns during the -the spore Bacillus subtilis var. niger. also known as B. globigii, or B.g.. in concentrations ranging from 103/ml to 106/ml -the vegetative bacterium. Erwinia herbicola. or E.h.. in concentrations ranging from 103/ml to 10 /rnl: -the RNA virus, MS2. in concentrations ranging from 105/ml to 105/ml; -and the protein. ovalbumin. in concentrations including 0.1 ng/ml to 100 ng/ml.
The miniFlo and its single-target assays produced both excellent quantification as well as detectionlidentification against the bacterial simulants B.g. and E. h. The performance of the Abbased assay for B.g.. the anthrax simulant. at JFT III was particularly good -100% of all unknowns with B.g. were correctly identified and quantified with no false positives on blanks at 103/mi sensitivity. Correct identification was also obtained for 94% of the E.h. samples, 77% of the MS2 samples, and 75% of the ovalbumin samples. All samples yielded less than 1% false positives. This illustrates the need for combining Ab-based assays with nucleic acid-based assays to eliminate false positives.
Real-time PCR Instrumentation
Under LLNL's internal support and support from DARPA, LLNL has designed, built, and with the collaboration of Roche Pharmaceuticals, Inc. successfully operated the world's first battery-powered. hand-held PCR and briefcase-sized, real-time PCR instruments, based on thermal cycling chambers made from etched and fusion-bonded silicon5. The unit that we sent to the Armed Forces Institure of Pathology is pictured in Figure 4. 203 Figure 3 . Photograph the miniFlo, the version that we took to the JET III. Both the briefcase instrument and the 10-chamber version utilize the Roche-patented Taqman® assay. which adds a second level of confirmation to the PCR assay. PCR normally derives its selectivity from the hybridization required for its primers to anneal to the target sequence before the amplification process can occur. The Taqman® assay adds an independent hybridization step with a separate probe that anneals onto the sequence being amplified. During the PCR amplification, the endonuclease activity of the enzyme cuts the Taqman® probe into separate nucleotides, releasing a fluorescent label from its nearby quencher, causing an increase in fluorescence as the amplification proceeds. Both the briefcase and the 10-chamber instruments monitor the fluorescence from the Taqman® probe during every thermal cycle, providing realtime data from the PCR reaction. This is particularly important when a rapid assay is valuable. since the time it takes to reach a detectable threshold with the Taqman® probe assay is inversely related to the starting concentration of the target organism. That is, you quickly know when there is a high concentration of an agent. Our initial characterizations of the automated fluidics system has used various sizes of latex beads as simulants for reagents. so that the flow-cytometric assay can measure the efficiacy of the mixing and transport processes. An example of the results of such a test are shown in Figure  7 . The data are presented in a 2-dimensional histogram or "dot plot". The vertical axis is the detected fluorescence and the horizontal axis is the small-angle elastic light scattering, or "forward scatter". The forward scatter is a measure of bead size. The solution being extracted from the aerosol collector contained the non-fluorescent beads. Notice that the three "reagent" beads were mixed into the assay in roughly equal proportions. Our short-term plans are to replace the latex beads with actual fluorescent-labeled antibody reagents and to spray bacterial spores into the aerosol collector. The dot-plot assay would then show two basic groups of particles -bacteria with fluorescence (caused by the binding of the labeled antibodies) and nonfluorescent bacteria. The focus of this effort will be to optimized the system to detect specific aerosolized bacteria at concentrations below 1 ACPLA. 
